Heather Franklin
Director/Board Member at XOMA CORPORATION
Net worth: - $ as of 29/04/2024
Profile
Heather L.
Franklin is the founder of Blaze Bioscience, Inc. (founded in 2011) where she holds the title of President, Chief Executive Officer & Director since 2013.
She is currently working as an Independent Director at XOMA Corp.
since 2021.
In her former positions, she worked as a Senior Manager-Research Operations Program at Amgen, Inc., Head-Project Management at AmpliPhi Biosciences Corp., and as SVP-Business Development & Alliance Management at ZymoGenetics, Inc. from 2008 to 2010.
Ms. Franklin has a graduate degree from the University of Washington, an undergraduate degree from The University of North Carolina at Charlotte, and an MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
XOMA CORPORATION
-.--% | 17/03/2024 | 0 ( -.--% ) | - $ | 29/04/2024 |
Heather Franklin active positions
| Companies | Position | Start |
|---|---|---|
| XOMA CORPORATION | Director/Board Member | 05/08/2021 |
Blaze Bioscience, Inc.
 Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | Founder | 31/12/2010 |
Former positions of Heather Franklin
| Companies | Position | End |
|---|---|---|
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 30/11/2010 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
| AMGEN INC. | Corporate Officer/Principal | - |
Training of Heather Franklin
| The University of North Carolina at Charlotte | Undergraduate Degree |
| University of Washington | Graduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| XOMA CORPORATION | Health Technology |
| Private companies | 3 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | Health Services |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Heather Franklin
